Proteomic changes related to actin cytoskeleton function in the skin of vildagliptin-treated mice

Vildagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) is a widely used type 2 diabetes medication that is associated with an up-to 10-fold increased risk for the development of bullous pemphigoid (BP), an autoimmune skin disease. The mechanism by which vildagliptin promotes the development of BP remains unknown.

Source: Journal of Dermatological Science - January 20, 2024 Category: Dermatology Authors: Antti N ätynki, Nina Kokkonen, Jussi Tuusa, Steffen Ohlmeier, Ulrich Bergmann, Kaisa Tasanen Source Type: research